Research Progress of Lymph Node Dissection in Treatment of cN0 Papillary Thyroid Microcarcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 CUIPeng ¹ , XUDe-quan ² , YINYue ² ,  DAIWen-jie ²

1. Department of General Surgery, Pudong Hospital of Shanghai, Shanghai 200210, China;
2. Department of Thyroid and Breast Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China;

Corresponding?author：

DAIWen-jie, Email: davidhmu@163.com

Keywords：

Papillary thyroid microcarcinoma; Central lymph node metastasis; Prophylactic central lymph node dissection

DOI：

10.7507/1007-9424.20150368

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To analyze the predictive factors for central lymph node metastasis in papillary thyroid microcarcinoma (PTMC), and explore the treatment method for the patients with PTMC. Method The literatures were reviewed according to the results searched from PubMed in recent years. Results Central lymph node metastases were common in the patients with PTMC. It was important for prophylactic central lymph node dissection so it might reduce the local recurrence and comfirm the clinical staging, further more provide the strategies for the postoperative therapy. Conclusions Lymphadenectomy is necessary for patients with lymph node metastasis. Prophylactic central lymph node dissection should be performed for patients without lymph node metastasis but with one risk factor or more.

Citation： CUIPeng, XUDe-quan, YINYue, DAIWen-jie. Research Progress of Lymph Node Dissection in Treatment of cN0 Papillary Thyroid Microcarcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(11): 1405-1409. doi: 10.7507/1007-9424.20150368 Copy

1.	?徐德全, 代文杰.甲狀腺髓樣癌的靶向治療.中國普外基礎與臨床雜志, 2014, 21(12):1579-1582.
2.	World Cancer Report. Version 2014. http://www.iarc.fr/en/publications/books/wcr/wcr-order.php.
3.	陳萬青, 張思維, 曾紅梅, 等.中國2010年惡性腫瘤發病與死亡.中國腫瘤, 2014, 23(1):1-10.
4.	Soares P, Celestino R, Gaspar Da Rocha A, et al. Papillary thyroid microcarcinoma:how to diagnose and manage this epidemic? Int J Surg Pathol, 2014, 22(2):113-119.
5.	Cupisti K, Lehwald N, Anlauf M, et al. Encapsulation status of papillary thyroid microcarcinomas is associated with the risk of lymph node metastases and tumor multifocality. Horm Metab Res, 2014, 46(2):138-144.
6.	Choi SJ, Kim TY, Lee JC, et al. Is routine central neck dissection necessary for the treatment of papillary thyroid microcarcinoma? Clin Exp Otorhinolaryngol, 2008, 1(1):41-45.
7.	Yu XM, Wan Y, Sippel RS, et al. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18445 cases. Ann Surg, 2011, 254(4):653-660.
8.	李建新, 楊雨民, 齊欣, 等.甲狀腺微小癌的診斷和治療.中國普外基礎與臨床雜志, 2012, 19(7):796-798.
9.	Kim BY, Jung CH, Kim JW, et al. Impact of clinicopathologic factors on subclinical central lymph node metastasis in papillary thyroid microcarcinoma. Yonsei Med J, 2012, 53(5):924-930.
10.	Rosai J, Livolsi VA, Sobrinho-Simoes M, et al. Renaming papillary microcarcinoma of the thyroid gland:the Porto proposal. Int J Surg Pathol, 2003, 11(4):249-251.
11.	Lang BH, Lo CY, Chan WF, et al. Prognostic factors in papillary and follicular thyroid carcinoma:their implications for cancer staging. Ann Surg Oncol, 2007, 14(2):730-738.
12.	王深明, 葉潤儀.甲狀腺微小癌診斷與外科治療規范化.中華普外科手術學雜志:電子版, 2013, 7(4):246-249.
13.	Zaydfudim V, Feurer ID, Griffin MR, et al. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery, 2008, 144(6):1070-1078.
14.	Wang Q, Chu B, Zhu J, et al. Clinical analysis of prophylactic central neck dissection for papillary thyroid carcinoma. Clin Transl Oncol, 2014, 16(1):44-48.
15.	Costa S, Giugliano G, Santoro L, et al. Role of prophylactic central neck dissection in cN0 papillary thyroid cancer. Acta Otorhinolaryngol Ital, 2009, 29(2):61-69.
16.	White ML, Gauger PG, Doherty GM. Central lymph node dissection in differentiated thyroid cancer. World J Surg, 2007, 31(5):895-904.
17.	NCCN Guidelines:Thyroid Carcinoma. Version 2, 2013.
18.	代文杰, 徐德全, 殷越.甲狀腺結節手術范圍合理選擇——美國及我國相關指南解讀.中國實用外科雜志, 2015, 35(6):604-607.
19.	Yoshida A. Guidelines for the management of thyroid tumors. Nihon Geka Gakkai Zasshi, 2012, 113(6):507-511.
20.	鄢丹桂, 張彬.甲狀腺乳頭狀癌臨床N0患者頸部淋巴結處理.中華耳鼻喉頭頸外科雜志, 2012, 47(3):257-260.
21.	Pai SI, Tufano RP. Central compartment neck dissection for thyroid cancer. ORL J Otorhinolaryngol Relat Spec, 2008, 70(5):292-297.
22.	徐德全, 代文杰.分化型甲狀腺癌術后促甲狀腺激素抑制性治療進展.中國實用外科雜志, 2013, 33(12):1071-1074.
23.	D?nil? R, Andriescu L, Grigorovici A, et al. Differentiated thyroid cancer-staging and prognostic systems. Rev Med Chir Soc Med Nat Iasi, 2005, 109(1):71-76.
24.	Shaha AR, Loree TR, Shah JP. Intermediate-risk group for differentiated carcinoma of thyroid. Surgery, 1994, 116(6):1036-1041.
25.	孫榮昊, 李超, 樊晉川.分化型甲狀腺癌外科治療要點問題分析-美國同行見解.中國實用外科雜志, 2014, 34(4):300-302.
26.	Niemeier LA, Kuffner Akatsu H, Song C, et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer, 2012, 118(8):2069-2077.
27.	Xu D, Lv X, Wang S, et al. Risk factors for predicting central lymph node metastasis in papillary thyroid microcarcinoma. Int J Clin Exp Pathol, 2014, 7(9):6199-6205.
28.	Cho SY, Lee TH, Ku YH, et al. Central lymph node metastasis in papillary thyroid microcarcinoma can be stratified according to the number, the size of metastatic foci, and the presence of desmoplasia. Surgery, 2015, 157(1):111-118.
29.	Hong YR, Yan CX, Mo GQ, et al. Conventional US, elastography, and contrast enhanced US features of papillary thyroid microcarcinoma predict central compartment lymph node metastases. Sci Rep, 2015, 5:7748.
30.	So YK, Son YI, Hong SD, et al. Subclinical lymph node metastasis in papillary thyroid microcarcinoma:a study of 551 resections. Surgery, 2010, 148(3):526-531.
31.	Vasileiadis I, Karakostas E, Charitoudis G, et al. Papillary thyroid microcarcinoma:clinicopathological characteristics and implications for treatment in 276 patients. Eur J Clin Invest, 2012, 42(6):657-664.
32.	Zhang L, Wei WJ, Ji QH, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma:a study of 1066 patients. J Clin Endocrinol Metab, 2012, 97(4):1250-1257.
33.	American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 2009, 19(11):1167-1214.
34.	Takami H, Ito Y, Okamoto T, et al. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J Surg, 2011, 35(1):111-121.
35.	田文, 羅晉.中國與美國甲狀腺結節與分化型甲狀腺癌診治指南比較.中國實用外科雜志, 2013, 33(6):475-479.
36.	Popadich A, Levin O, Lee JC, et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery, 2011, 150(6):1048-1057.
37.	Hartl DM, Leboulleux S, Al Ghuzlan A, et al. Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma. Ann Surg, 2012, 255(4):777-783.

1. ?徐德全, 代文杰.甲狀腺髓樣癌的靶向治療.中國普外基礎與臨床雜志, 2014, 21(12):1579-1582.
2. World Cancer Report. Version 2014. http://www.iarc.fr/en/publications/books/wcr/wcr-order.php.
3. 陳萬青, 張思維, 曾紅梅, 等.中國2010年惡性腫瘤發病與死亡.中國腫瘤, 2014, 23(1):1-10.
4. Soares P, Celestino R, Gaspar Da Rocha A, et al. Papillary thyroid microcarcinoma:how to diagnose and manage this epidemic? Int J Surg Pathol, 2014, 22(2):113-119.
5. Cupisti K, Lehwald N, Anlauf M, et al. Encapsulation status of papillary thyroid microcarcinomas is associated with the risk of lymph node metastases and tumor multifocality. Horm Metab Res, 2014, 46(2):138-144.
6. Choi SJ, Kim TY, Lee JC, et al. Is routine central neck dissection necessary for the treatment of papillary thyroid microcarcinoma? Clin Exp Otorhinolaryngol, 2008, 1(1):41-45.
7. Yu XM, Wan Y, Sippel RS, et al. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18445 cases. Ann Surg, 2011, 254(4):653-660.
8. 李建新, 楊雨民, 齊欣, 等.甲狀腺微小癌的診斷和治療.中國普外基礎與臨床雜志, 2012, 19(7):796-798.
9. Kim BY, Jung CH, Kim JW, et al. Impact of clinicopathologic factors on subclinical central lymph node metastasis in papillary thyroid microcarcinoma. Yonsei Med J, 2012, 53(5):924-930.
10. Rosai J, Livolsi VA, Sobrinho-Simoes M, et al. Renaming papillary microcarcinoma of the thyroid gland:the Porto proposal. Int J Surg Pathol, 2003, 11(4):249-251.
11. Lang BH, Lo CY, Chan WF, et al. Prognostic factors in papillary and follicular thyroid carcinoma:their implications for cancer staging. Ann Surg Oncol, 2007, 14(2):730-738.
12. 王深明, 葉潤儀.甲狀腺微小癌診斷與外科治療規范化.中華普外科手術學雜志:電子版, 2013, 7(4):246-249.
13. Zaydfudim V, Feurer ID, Griffin MR, et al. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery, 2008, 144(6):1070-1078.
14. Wang Q, Chu B, Zhu J, et al. Clinical analysis of prophylactic central neck dissection for papillary thyroid carcinoma. Clin Transl Oncol, 2014, 16(1):44-48.
15. Costa S, Giugliano G, Santoro L, et al. Role of prophylactic central neck dissection in cN0 papillary thyroid cancer. Acta Otorhinolaryngol Ital, 2009, 29(2):61-69.
16. White ML, Gauger PG, Doherty GM. Central lymph node dissection in differentiated thyroid cancer. World J Surg, 2007, 31(5):895-904.
17. NCCN Guidelines:Thyroid Carcinoma. Version 2, 2013.
18. 代文杰, 徐德全, 殷越.甲狀腺結節手術范圍合理選擇——美國及我國相關指南解讀.中國實用外科雜志, 2015, 35(6):604-607.
19. Yoshida A. Guidelines for the management of thyroid tumors. Nihon Geka Gakkai Zasshi, 2012, 113(6):507-511.
20. 鄢丹桂, 張彬.甲狀腺乳頭狀癌臨床N0患者頸部淋巴結處理.中華耳鼻喉頭頸外科雜志, 2012, 47(3):257-260.
21. Pai SI, Tufano RP. Central compartment neck dissection for thyroid cancer. ORL J Otorhinolaryngol Relat Spec, 2008, 70(5):292-297.
22. 徐德全, 代文杰.分化型甲狀腺癌術后促甲狀腺激素抑制性治療進展.中國實用外科雜志, 2013, 33(12):1071-1074.
23. D?nil? R, Andriescu L, Grigorovici A, et al. Differentiated thyroid cancer-staging and prognostic systems. Rev Med Chir Soc Med Nat Iasi, 2005, 109(1):71-76.
24. Shaha AR, Loree TR, Shah JP. Intermediate-risk group for differentiated carcinoma of thyroid. Surgery, 1994, 116(6):1036-1041.
25. 孫榮昊, 李超, 樊晉川.分化型甲狀腺癌外科治療要點問題分析-美國同行見解.中國實用外科雜志, 2014, 34(4):300-302.
26. Niemeier LA, Kuffner Akatsu H, Song C, et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer, 2012, 118(8):2069-2077.
27. Xu D, Lv X, Wang S, et al. Risk factors for predicting central lymph node metastasis in papillary thyroid microcarcinoma. Int J Clin Exp Pathol, 2014, 7(9):6199-6205.
28. Cho SY, Lee TH, Ku YH, et al. Central lymph node metastasis in papillary thyroid microcarcinoma can be stratified according to the number, the size of metastatic foci, and the presence of desmoplasia. Surgery, 2015, 157(1):111-118.
29. Hong YR, Yan CX, Mo GQ, et al. Conventional US, elastography, and contrast enhanced US features of papillary thyroid microcarcinoma predict central compartment lymph node metastases. Sci Rep, 2015, 5:7748.
30. So YK, Son YI, Hong SD, et al. Subclinical lymph node metastasis in papillary thyroid microcarcinoma:a study of 551 resections. Surgery, 2010, 148(3):526-531.
31. Vasileiadis I, Karakostas E, Charitoudis G, et al. Papillary thyroid microcarcinoma:clinicopathological characteristics and implications for treatment in 276 patients. Eur J Clin Invest, 2012, 42(6):657-664.
32. Zhang L, Wei WJ, Ji QH, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma:a study of 1066 patients. J Clin Endocrinol Metab, 2012, 97(4):1250-1257.
33. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 2009, 19(11):1167-1214.
34. Takami H, Ito Y, Okamoto T, et al. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J Surg, 2011, 35(1):111-121.
35. 田文, 羅晉.中國與美國甲狀腺結節與分化型甲狀腺癌診治指南比較.中國實用外科雜志, 2013, 33(6):475-479.
36. Popadich A, Levin O, Lee JC, et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery, 2011, 150(6):1048-1057.
37. Hartl DM, Leboulleux S, Al Ghuzlan A, et al. Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma. Ann Surg, 2012, 255(4):777-783.

Previous Article
Pharmacological Mechanism of Tamoxifen and Its Influence on Ovary Function
Next Article
Research Progress of Preoperative Regional-arterial Chemotherapy in Advanced Gastric Cancer

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research Progress of Lymph Node Dissection in Treatment of cN0 Papillary Thyroid Microcarcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content